Dibenz(a,h)anthracene


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D000230 Adenocarcinoma PMID:21863085
MESH:D000236 Adenoma PMID:21863085; PMID:8571376
MESH:D001161 Arteriosclerosis PMID:3142695
MESH:D002277 Carcinoma PMID:21863085
MESH:D006390 Hemangioendothelioma PMID:21863085
MESH:D007153 Immunologic Deficiency Syndromes PMID:8571374
MESH:D007680 Kidney Neoplasms PMID:21863085
MESH:D008113 Liver Neoplasms PMID:21863085
MESH:D008175 Lung Neoplasms PMID:21863085; PMID:8571376; PMID:9659573
MESH:D009336 Necrosis PMID:17961608
MESH:D009374 Neoplasms, Experimental PMID:6850980
MESH:D010212 Papilloma PMID:21863085
MESH:D011041 Poisoning PMID:1309687
MESH:D012509 Sarcoma PMID:21863085
MESH:D012878 Skin Neoplasms PMID:21863085
MESH:D013274 Stomach Neoplasms PMID:21863085
MESH:D015674 Mammary Neoplasms, Animal PMID:21863085
MESH:D048629 Micronuclei, Chromosome-Defective PMID:26603514

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.